{"id":"NCT00803049","sponsor":"Sanofi","briefTitle":"Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis","officialTitle":"Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-10","primaryCompletion":"2015-12","completion":"2015-12","firstPosted":"2008-12-05","resultsPosted":"2017-01-30","lastUpdate":"2017-01-30"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Teriflunomide (HMR1726)","otherNames":["Aubagio"]}],"arms":[{"label":"Placebo/Teriflunomide 7 mg","type":"EXPERIMENTAL"},{"label":"Teriflunomide 7 mg/7 mg","type":"EXPERIMENTAL"},{"label":"Placebo/Teriflunomide 14 mg","type":"EXPERIMENTAL"},{"label":"Teriflunomide 14 mg/14 mg","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study was to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) participants with relapse.\n\nThe secondary objective was to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI) parameters.","primaryOutcome":{"measure":"Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)","timeFrame":"Baseline (LTS6050) up to 28 days after last dose of study drug up to 450 weeks","effectByArm":[{"arm":"Placebo/Teriflunomide 7 mg","deltaMin":93.8,"sd":null},{"arm":"Teriflunomide 7 mg/7 mg","deltaMin":91.3,"sd":null},{"arm":"Placebo/Teriflunomide 14 mg","deltaMin":94.4,"sd":null},{"arm":"Teriflunomide 14 mg/14 mg","deltaMin":91.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":116,"countries":["United States","Austria","Canada","Chile","Czechia","Denmark","Estonia","Finland","France","Germany","Italy","Netherlands","Norway","Poland","Portugal","Russia","Sweden","Switzerland","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["35485424","33023488","31198103","28680917"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":129},"commonTop":["Nasopharyngitis","Headache","Influenza","Urinary tract infection","Alanine aminotransferase increased"]}}